RxDoctor Payments Data

Mikio Ranahan

Pain Medicine · Chapel Hill, NCNPI 1437544053

Payments from drug & device makers

$4,501in general payments, 2019–2025

Across 136 payments — averaging $33.10 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Boston Scientific$2K
  • Collegium Pharmaceutical, Inc.$780
  • Nevro Corp.$704
  • AbbVie$424
  • Avanos Medical$210
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$180
  • plus $690 from 16 others

What the payments were for

  • Travel & lodging$89320%
  • Food & beverage$3,60880%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,501 in reported general payments places this provider in the 50th percentile of 182 pain medicine providers in North Carolina.

See all pain medicine providers in North Carolina

Medicare billing

Part B allowed, 2024
$176,705
Medicare patients
393
Services billed
2,105

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen877$20,923
Buprenorphine72$18,692
Xtampza ErOxycodone Myristate33$17,029
Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen448$13,410
BelbucaBuprenorphine Hcl18$12,239
LinzessLinaclotide11$5,596
Naloxone Hcl70$5,141
Nortriptyline Hcl255$3,630
Gabapentin214$3,438
Pregabalin96$2,488
Baclofen119$2,376
Duloxetine Hcl97$2,142
Tramadol Hcl212$1,829
Tizanidine Hcl64$923
Tramadol Hcl ErTramadol Hcl19$880

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Collegium Pharmaceutical, Inc.Xtampza Er, Belbuca$780$29,26951 claims
AbbVieLinzess$424$5,59611 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 182 pain medicine providers in North Carolina.

Other pain medicine in Chapel Hill

See the full list for North Carolina

Where these figures come from

Is this you, or does something look wrong? →